Cambrex has begun construction of a new research and development facility at its Milan site, representing a $30 million investment. To mark its 80th anniversary, the company will add analytical method development and process research and development capabilities and renovate several production plants. Completion is expected in the second half of 2027.
Cambrex, a global contract development and manufacturing organization, announced that it has begun construction of a new research and development facility at its site in Milan, Italy. The investment totals $30 million and will add advanced analytical method development and process research and development capabilities, while several production plants will also be renovated.
The expansion of the Milan site coincides with the company’s 80th anniversary, with completion targeted for the second half of 2027. Cambrex is also pursuing the acquisition of land adjacent to the site in response to future growth and demand for CDMO services, establishing a foundation for long-term business expansion and innovation.
Cambrex’s Milan site has a long track record of supporting the development and manufacture of pharmaceuticals, and the investment is intended to take the site’s scientific expertise and manufacturing capabilities into their next phase of growth. Company representatives described the start of construction on the new facility as a testament to the site’s track record.
Through this initiative, Cambrex aims to strengthen its role as a hub for pharmaceutical development and manufacturing in Europe and enhance its ability to meet the increasing complexity of small-molecule therapeutics.